SpineGuard has reached an exclusive distribution agreement with XinRong Medical Group for PediGuard in China, Hong Kong and Macau.
China’s spine market has become the world’s second-largest market after the USA and is expected to be worth over US$1 billion by 2019, driven by an aging population, increasing disease prevalence and treatment rates, along with growing affordability. The PediGuard system was approved by the China Food and Drug Administration (CFDA) in July 2015.
“The number of spine fusions continues to grow rapidly across the country… Since its clearance by CFDA, numerous Chinese orthopaedists and neurosurgeons have expressed a strong interest for our Dynamic Surgical Guidance technology.” says Pierre Jérôme, chief executive officer and co-founder of SpineGuard.
“Ease of use, cost effectiveness, accuracy, and safety are the benefits that we want to bring to surgeons in China, through which we will continue to realise our vision of putting patients first,” adds Christine Zhang, XinRong Medical Group’s chief executive officer.